Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00730522
Recruitment Status : Terminated (To conserve remaining capital, Sponsor decided to terminate the study early.)
First Posted : August 8, 2008
Last Update Posted : August 1, 2012
Information provided by (Responsible Party):
Catalyst Pharmaceuticals, Inc.

Brief Summary:
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).

Condition or disease Intervention/treatment Phase
Methamphetamine Dependence Drug: CPP-109 vigabatrin Drug: Matching Placebo Phase 2

Detailed Description:

This is a Phase II, randomized, double-blind, placebo-controlled, intent-to-treat, 2-arm, parallel design, multicenter study to evaluate vigabatrin as a treatment for methamphetamine addiction. The study will involve approximately 180 subjects (90/group) who meet DSM IV criteria for methamphetamine dependence. Subjects will be evaluated for their compliance with protocol inclusion/exclusion criteria during Screening/Baseline Phase, lasting up to 4 weeks.

At the conclusion of the Screening/Baseline Phase, subjects meeting all inclusion/exclusion criteria will be randomized to one of two treatment groups: vigabatrin or placebo. Subjects will proceed to a 12 week Treatment Phase and then undergo a 12 week follow-up period. Subjects will be scheduled for clinic visits 3 times per week for efficacy and/or safety assessments during the Screening/Baseline Phase and the 12 week Treatment Phase. Subjects will return for follow up visits at Weeks 13, 16, 20 and 24.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Vigabatrin for Treatment of Methamphetamine Dependence: A Phase II Study
Study Start Date : July 2008
Primary Completion Date : June 2009
Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
CPP-109 vigabatrin tablets
Drug: CPP-109 vigabatrin
tablets, bid for 12 weeks
Other Names:
  • GVG
  • gamma-vinyl GABA
Placebo Comparator: 2
Matching Placebo Tablets
Drug: Matching Placebo
tablets, bid, 12 weeks

Primary Outcome Measures :
  1. The proportion of subjects in each treatment group who are amphetamine abstinent during the last 2 weeks of the Treatment Phase (Weeks 11 and 12). [ Time Frame: Weeks 11-12 ]

Secondary Outcome Measures :
  1. • Number of methamphetamine negative urines during the Treatment Phase • Number of methamphetamine use weeks during the Treatment Phase. [ Time Frame: Weeks 1-12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Able to understand the study and provide written informed consent.

  • Male or female at least 18 years of age.
  • Meets DSM-IV (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition) criteria for methamphetamine dependence as major diagnosis, as determined by the Substance Abuse module of SCID (Structured Clinical Interview for DSM-IV).
  • Provides at least one urine specimen which is positive for methamphetamine according to a rapid screening test.
  • Seeking treatment for methamphetamine dependence.
  • Have normal visual fields.
  • Be in generally good health based on history, physical examination and laboratory findings.
  • If female of childbearing potential, use acceptable contraceptive methods

Exclusion Criteria:

  • Has current dependence on any psychoactive substance other than methamphetamine, alcohol, nicotine, or cannabinoid or physiologic dependence on alcohol requiring medical detoxification.
  • Has any serious medical or psychiatric illness and/or clinically significant abnormal laboratory values.
  • Has history of serious cardiovascular reaction to methamphetamine.
  • Has clinically significant cardiovascular impairment, abnormal ECG or uncontrolled hypertension.
  • Be under court or other governmental agency (e.g. social services) mandate to obtain treatment or requiring outside urine monitoring.
  • Be enrolled in an opiate substitution treatment program within 2 months of randomization.
  • Has ever taken vigabatrin in the past.
  • Is pregnant or lactating.
  • Has clinically significant ophthalmologic disease, which would preclude safety monitoring, is undergoing treatment for ocular disease or intends to have any ocular surgery or procedure performed during the time of their participation in the trial.
  • Has received a drug with known major organ toxicity, including retinotoxicity.
  • Is currently participating in, or has been enrolled in another clinical trial within the last 30 days.
  • Be anyone who, in the judgment of the investigator, would not be expected to attend regular study visits or to complete the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00730522

United States, California
North County Clinical Research (NCCR)
Oceanside, California, United States
South Bay Treatment Center
San Diego, California, United States
Addiction Pharmacology Research Laboratory, St. Luke's Hospital
San Francisco, California, United States
United States, Missouri
START Research and Treatment
Kansas City, Missouri, United States
United States, Nebraska
Creighton University Medical Center
Omaha, Nebraska, United States
United States, New Mexico
Behavioral Health Research Center of the Southwest
Albuquerque, New Mexico, United States
United States, Oklahoma
Pahl Pharmaceutical Research
Oklahoma City, Oklahoma, United States
United States, Texas
Pillar Research
Dallas, Texas, United States
Sponsors and Collaborators
Catalyst Pharmaceuticals, Inc.
Study Director: Charles W Gorodetzky, MD, PhD Catalyst Pharmaceuticals, Inc.

Responsible Party: Catalyst Pharmaceuticals, Inc. Identifier: NCT00730522     History of Changes
Other Study ID Numbers: CPP-02001
First Posted: August 8, 2008    Key Record Dates
Last Update Posted: August 1, 2012
Last Verified: July 2012

Keywords provided by Catalyst Pharmaceuticals, Inc.:

Additional relevant MeSH terms:
Central Nervous System Stimulants
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors
Enzyme Inhibitors
GABA Agents